V enous thromboembolism (VTE) is a leading cause of morbidity and mortality during pregnancy. Although VTE is a rare disease in women of childbearing age, VTE affects pregnant women five times more frequently than nonpregnant women of similar age (1) . It has been reported to complicate 1 in 1,000 to 1 in 2,000 pregnancies (2, 3) , although the true incidence may be between three to ten times higher than this (3) . Venous thromboembolic disease has been reported to occur with two to three times this frequency in the puerperal period, defined as the 2-month period following delivery (4) . Since venous thromboembolic disease is often asymptomatic, clinical suspicion must remain high in order to appropriately diagnose and treat these women.
In recent years, pulmonary embolism has surpassed infection, hemorrhage, and preeclampsia-eclampsia to become a leading cause of maternal mortality in the United States (5) (6) (7) (8) . This change in epidemiology likely reflects both an increase in the diagnosis of venous thromboembolic disease due to improved diagnostic methods and improvements in the medical management of infection, hemorrhage, and preeclampsia-eclampsia, more than an increase in the incidence of venous thromboembolic disease. However, it is evident that VTE remains a significant cause of maternal morbidity and mortality.
Clinical suspicion is critical to the diagnosis of VTE. However, many of the classic symptoms of venous thromboembolic disease, including tachycardia, tachypnea, dyspnea, and leg swelling, may also be associated with a normal pregnancy (9, 10) . Refuerzo et al. (3) performed a retrospective review of the clinical signs and symptoms in patients who, during pregnancy or within 6 wks postpartum, were suspected to have a pulmonary embolism (PE). The authors found no difference in clinical signs or symptoms between those with a PE and those without (3) . Risk factors for VTE in the antenatal period include maternal age Ͼ35 yrs, parity of three or greater, weight Ͼ165 lbs, a personal or family history of deep vein thrombosis (DVT) or PE, varicose veins, smoking, or known antiphospholipid syndrome or other hypercoagulable state (1) (2) (3) . Several obstetric complications have also been shown to be associated with increased risk of thromboembolic disease in the peripartum and puerperal periods, including prolonged bed rest, instrument-assisted delivery or surgical delivery, hemorrhage, and sepsis (11) .
Historically, it has been reported that the late third trimester and immediate postpartum period was the highest risk period for DVT and PE. However, more recent studies have shown that the risk of DVT is highest in the antenatal period, with as many as 16 -33% occurring in the first trimester (2, 11, 12) . This epidemiologic shift is most likely due to changing obstetric practices surrounding delivery, such as early ambulation after delivery rather than prolonged bed rest, and a decrease in the use of oral estrogens to suppress lactation (11) . Despite the distribution of DVT throughout pregnancy, however, the immediate postpartum period continues to be a high-risk period for pulmonary embolism (2) . This risk has been found to be significantly increased by instrument-assisted or surgical deliv-ery and most notably increased by emergent cesarean section (2, 13) .
Although DVT is frequently asymptomatic and is particularly challenging to diagnose in the pregnant population, it is still important to recognize this presentation of venous thromboembolic disease if possible. If venous thrombosis remains untreated, 15-24% of these patients will develop pulmonary embolism (2, 14, 15) . PE during pregnancy may be fatal in almost 15% of patients, and in 66% of these, death will occur within 30 mins of the embolic event (2, 14) .
Pathophysiology
A normal pregnancy induces a hypercoagulable state. This hypercoagulable state is multifactorial and is thought to be due to a combination of physical and hormonal factors as well as hematologic changes.
The physical and hormonal changes of pregnancy begin early in the first trimester. Progesterone-mediated increases in venous distensibility and capacity are apparent in the first trimester (2, 11) and result in increased venous stasis. Pregnancy-related DVTs have a remarkable left-sided predominance, and although the exact mechanism of this is unknown, it is likely due to more significant stasis in the left-sided venous system. During pregnancy, the right iliac artery has a compressive effect on the left common iliac vein (2) . The enlarging uterus may also induce a selective compressive effect on the common iliac vein (2) .
The hematologic changes of pregnancy are also important in the pathophysiology of venous thromboembolic disease and include increased circulating levels of clotting factors as well as changes in fibrin generation and fibrinolysis. Circulating levels of multiple clotting factors, including factors I, II, VII, VIII, IX, and X, have been shown to be elevated in pregnancy and the puerperium (2, 11) . Protein S levels, both protein-bound and free levels, have been shown to decline with increasing gestation (16) , although protein C activity appears to be unaffected (13) . Platelet activation is increased, which may reflect the acute phase response. The generation of fibrin is also increased, most notably in the third trimester, and fibrinolytic activity is decreased (2, 11) . The combination of these factors results in a hypercoagulable state.
Diagnosis
Venous thromboembolic disease is challenging to diagnose during pregnancy. Clinical suspicion is warranted due to the hypercoagulable state, which begins early during the first trimester and continues throughout the puerperium, as well as the risk factors associated with pregnancy. However, the classic symptoms of VTE are less specific during pregnancy. Leg swelling (17) and pain (17) , dyspnea (9, 10, 17, 18) , tachypnea (10, 17) , tachycardia (9) , and palpitations (9) are symptoms common among normal pregnant women and tend to increase toward the end of gestation. Therefore, the diagnosis can be confirmed only by objective testing.
The diagnosis of venous thromboembolic disease during pregnancy is often impaired or delayed by a reluctance to expose a pregnant patient and her fetus to ionizing radiation. Epidemiologic studies have demonstrated that exposure of radiation doses of less than a total of 5 rad (50,000 Gy) has not been associated with significant risk of fetal injury (17) . Although there have been reports that gestational exposure to 5 rad of ionizing radiation may increase the risks of some childhood cancers (19) , most diagnostic procedures for VTE expose the fetus to a small fraction of this amount of radiation (discussed subsequently) and entail only a very small risk of subsequent problems.
Diagnosis of DVT
Contrast Venography. Contrast venography is the accepted gold standard for diagnosing DVT (20) . However, since it involves radiation exposure and an invasive procedure, it has largely been replaced by compression ultrasound (CUS) and impedance plethysmography (IPG) (21) .
Compression Ultrasound. CUS is a noninvasive test with a sensitivity of 97% and a specificity of 94% for the diagnosis of symptomatic, proximal DVT in the general population (21) . CUS does not involve any radiation exposure and is without any known risks to mother or fetus. This makes it a reasonable first test for the diagnosis of DVT in pregnancy. CUS, however, is less accurate for isolated calf DVT, which comprises approximately 20% of symptomatic DVTs (22) . CUS alone is also inadequate for isolated iliac vein thrombosis, and as these proximal thrombi carry a very high risk for embolization, it is important to recognize those cases that may need further testing in the setting of a negative ultrasound. Both computed tomography (CT) scan and magnetic resonance imaging have been used to diagnose proximal DVT, but magnetic resonance imaging is the only test that has been demonstrated to have a high degree of sensitivity and specificity for iliac vein thrombosis (20) .
Impedance Plethysmography. IPG is also used in the diagnosis of DVT. IPG is noninvasive and works by applying a high-frequency continuous current to the limb and measuring increased venous outflow resistance, or a reduction in the electrical impedance, in the deep veins of the proximal lower extremities (23) . Since the basis of this test is the impedance of blood flow, it is insensitive for nonobstructing thrombi, including the majority of isolated calf DVT as well as nonobstructive proximal thrombi. IPG is not as accurate as CUS for the diagnosis of DVT in the femoral, superficial femoral, or popliteal veins (22) , but it has the advantage of increased sensitivity for more proximal DVT. IPG has been found to be safe throughout pregnancy (24) , with no exposure to ionizing radiation. IPG does not require highly specific technical training to perform, but its accuracy depends on proper patient positioning and attention to technique.
D-Dimer. D-dimer testing has a role in the diagnosis of DVT and PE in the nonpregnant population, although its usefulness during pregnancy is controversial. The plasma D-dimer level measures the degradation products of cross-linked fibrin in the circulation, which are produced during fibrinolysis of a clot. When the D-dimer is measured using highprecision tests such as an enzyme-linked immunosorbent assay, D-dimer levels are sensitive for venous thromboembolism. However, there are multiple assays available to measure D-dimer levels, and the sensitivities and specificities of these tests vary widely. The sensitivities have been noted to range from almost 100% to as low as 80% (25) . Highly sensitive tests, such as the standard or rapid enzymelinked immunosorbent assays, have high false positive rates but have a high negative predictive value given a negative test. The less sensitive assays including latex agglutination or red-cell agglutination have a lower false-positive rate but cannot safely be used alone to rule out DVT or VTE. However, these tests are difficult to use meaningfully during pregnancy, as there are no studies that we are aware of that have established the negative predictive value of any D-dimer test during pregnancy. Also, pregnancy alone, as well as many other clinical conditions, may elevate the plasma D-dimer level in the absence of thromboembolic disease. Ddimer values increase throughout pregnancy with increasing gestational age and are significantly elevated in patients with preterm labor, preeclampsia, and placental abruption (26) . D-dimer levels may also be elevated in patients with recent surgery, underlying malignancy, or increased age (20) .
Therefore, although it is reasonable to test a pregnant patient with a highly sensitive D-dimer assay, the results must be taken in the context of the clinical scenario. If this test is negative in a patient with another reason for her symptoms, no further diagnostic testing may be warranted. However, in a patient with a high pretest probability of VTE, or a patient with a positive D-dimer, the diagnostic workup should continue with a CUS or IPG to evaluate for DVT, or a CT scan or ventilation-perfusion (VQ) scan to diagnose pulmonary embolism.
Diagnosis of PE. The diagnosis of PE frequently begins with the clinical presentation and routine laboratory information, such as chest pain, tachypnea, tachycardia, hypoxia, and abnormalities on the electrocardiogram, chest radiograph, and arterial blood gas. However, this presentation is neither sensitive nor specific for pulmonary embolism, and it is insufficient for diagnosis. Given the particular motivation to avoid exposure to ionizing radiation during pregnancy, it may be reasonable to begin the diagnostic workup with either a compression ultrasound or an IPG and, if positive, to treat for venous thromboembolic disease without further testing for a pulmonary embolism. If that decision is made, however, a negative ultrasound or IPG would indicate the need for further testing for PE.
Several diagnostic algorithms have been proposed for nonpregnant patients, which include combining the results of a VQ or CT scanning with pretest probability, D-dimer testing, and ultrasonography. However, pregnant patients were excluded from the studies that validated these diagnostic models, and extrapolating these data to pregnant women is problematic. The utility of D-dimer testing for the exclusion of PE in pregnant women is uncertain, and the signs used for determining pretest probability in the structured model, for example, heart rate of 100 beats/min and leg swelling, are common physiologic findings during pregnancy. Also, the prevalence of PE among pregnant women with suspected PE is not as well established (20) and may differ from that of the nonpregnant population, thereby affecting the positive predictive value of diagnostic tests.
Pulmonary Angiogram. Pulmonary angiography is considered the gold standard for diagnosis of pulmonary embolism, but its use in clinical practice continues to decline. Because the test is invasive and requires expertise for performance and for interpretation, its use is reserved for those patients in whom pulmonary embolism cannot be diagnosed or reasonably excluded with less invasive testing. However, modern techniques and newer contrast materials have made pulmonary angiography substantially safer. The contrast load of pulmonary angiography is similar to a helical CT scan, with each side of a pulmonary angiogram using approximately half the contrast load of a helical CT scan (27) . The exposure to ionizing radiation depends on the number of films, but on average, the fetal radiation exposure from a pulmonary angiogram (20) is less than that of a helical CT scan (15) except during the first trimester. Pulmonary angiography may be a useful diagnostic technique in pregnant and nonpregnant patients alike.
Ventilation-Perfusion Scan. VQ scanning is an appropriate first step in the diagnosis of pulmonary embolism. It is considered safe to perform throughout pregnancy. The amount of radiation exposure varies based on the isotope used, but all methods are within the safe range for use during pregnancy and range between 0.006 and 0.018 rad for the perfusion scan and between 0.001 and 0.035 rad for the ventilation scan (15, 20) .
Nonpregnant patients who undergo a VQ scan can be divided into three categories: normal (no perfusion defects in all views), high probability (segmental or greater defects with normal ventilation), or nondiagnostic (28) . In the setting of a normal VQ scan, pulmonary embolism can safely be ruled out. If the result is a high-probability VQ scan, the patient should be treated for pulmonary embolism in most circumstances. With a nondiagnostic test, pulmonary embolism cannot be excluded. The studies validating this approach excluded pregnant women, but it is reasonable to deal with pregnant patients similarly. The PIOPED researchers found that a VQ scan was diagnostic in 27% of nonpregnant patients, with 13% of patients having a high-probability scan and 14% having a normal or near-normal scan (29) . Another 9% had a low-probability scan, which in nonpregnant patients may be sufficient to rule out pulmonary embolism if there is a low pretest clinical likelihood of PE. The remaining 64% of patients had a nondiagnostic test, warranting further testing. However, it is not clear whether these numbers would be the same for pregnant patients. Pregnant women tend to be a young population, with low incidence of underlying lung disease, and this may decrease the likelihood of a nondiagnostic VQ scan.
If VQ scanning is used during pregnancy, it may be beneficial to perform perfusion scanning alone first, since this decreases the radiation exposure for the woman and the fetus. If there are no perfusion defects, the scan can be considered negative. The ventilation portion of the test (or in some cases a chest film alone) (30) is useful to distinguish unmatched perfusion defects from matched defects.
Technetium-99 is renally excreted and collects in the bladder, which increases the fetal radiation exposure by the proximity of the radioactive material. Encouraging fluid intake and frequent voiding for 4 -6 hrs after the test can minimize this exposure. Technetium-99 is also excreted in breast milk, so postpartum women who undergo VQ scanning should substitute formula for breast milk for 2 days.
Helical CT Scan. Helical CT angiography has provided an alternative method to visualize pulmonary emboli. Although there is frequently reluctance to expose a pregnant woman to a CT scan, both by practitioners and by the pregnant patients, a recent study found that the dose of ionizing radiation from a helical CT was safe in all trimesters (15) . This study calculated the mean fetal radiation dose by measuring maternal-fetal geometry and the position of the fetus and using a Monte Carlo technique to determine the energy deposition in water-equivalent ellipsoid phantoms using the geometrics of the study patients. The most caudal section of the CT scan was 5 mm inferior to the xiphoid process, and the determination of radiation exposure by trimester was calculated based on fundal height and the distance of the fetus from the xiphoid process. The radiation doses to
CT scanners continue to provide newer technology, faster scanning times, increased sensitivity, and better resolution. The sensitivities of spiral CT scans reported in the literature vary from 57% to 100%, with reported specificities between 64% and 100% (20, 25, (31) (32) (33) . Both the sensitivity and specificity are affected by the location of the embolus. Helical CT is more sensitive for emboli in the central arteries and less sensitive for subsegmental emboli (27) . However, a CT scan that is negative for pulmonary embolism may diagnose other abnormalities that are responsible for the patient's symptoms.
Treatment. Heparin is the mainstay of therapy for acute venous thromboembolic disease during pregnancy. Heparin is a large molecule and does not cross the placenta (34), so it does not carry risks of fetal hemorrhage or teratogenesis. The major complications of heparin are maternal, including maternal hemorrhage, heparin-induced thrombocytopenia, and heparin-induced osteopenia. Hemorrhage at the uteroplacental junction is a rare but potentially devastating complication of anticoagulation. However, the bleeding risks to pregnant women treated with heparin appear to be comparable to those of nonpregnant patients treated with heparin or warfarin.
Pregnant patients may require higher doses of heparin to achieve therapeutic anticoagulation. Heparin requirements appear to increase during pregnancy due to increased circulating levels of heparin binding proteins, increased plasma volume, increased renal clearance due to increased glomerular filtration, and increased heparin degradation by the placenta (35) (36) (37) . The dose requirements may be as high as two times the normal weight-based dose (37) .
Thrombocytopenia associated with heparin use manifests in two presentations. Heparin-associated thrombocytopenia is usually mild, reversible, and selflimited, even with continued exposure to heparin (38) . This form of thrombocytopenia is not immune-mediated, and no heparin-dependent antibodies are present. It is thought to be due to platelet aggregation from a direct effect of heparin. It occurs early in the course of heparin therapy, usually within 4 days, and affects as many as 30% of patients receiving heparin.
Heparin-induced thrombocytopenia, or HIT, on the other hand, is immunemediated, and antibodies to heparin are detectible. This condition occurs in 1-3% of nonpregnant patients treated with unfractionated heparin (38, 39) . The spectrum of HIT encompasses a range of presentations, including asymptomatic antibodies without thrombocytopenia, thrombocytopenia, and thrombocytopenia with thrombosis. Untreated, the mortality rate of HIT with new thromboembolic complications is 20 -30%, and there is risk of significant morbidity from arterial and venous thrombosis.
It was anticipated that the use of low molecular weight heparin (LMWH) for treatment of VTE might be associated with a decreased risk of HIT (39) , but this has not been verified by the current available literature. Although the incidence of HIT associated with LMWH use has not been established, several studies have found no statistically significant difference in the incidence of HIT between unfractionated heparin and LMWH (40) .
Heparin use has also been associated with osteopenia in pregnant women. This osteopenia has been linked to the inhibition of formation of 1,25 dihydroxyvitamin D, the active metabolite of vitamin D (41) (42) (43) . One study found that heparin adversely affected bone density in approximately one third of exposed pregnant patients, although the long-term impact of this bone loss on fracture risk has not been established (44) . This study found that the bone loss was greater than the bone loss of pregnant patients who were not treated with heparin, although other studies have suggested that bone loss is a normal part of pregnancy and lactation, and that women treated with heparin have no greater bone loss than normal pregnant and lactating women (45, 46) . Low Molecular Weight Heparin or Unfractionated Heparin? LMWHs, like unfractionated heparin, do not cross the placenta and therefore are not believed to carry any increased risk of fetal hemorrhage or teratogenesis. Aventis Pharmaceuticals briefly issued a precaution about possible teratogenic effects associated with enoxaparin sodium, but this warning has been removed from the package label reflecting the fact that LMWH is considered a safe alternative to unfractionated heparin during pregnancy.
Although LMWH appears to be safe for use during pregnancy, the dosing of this drug during pregnancy is not straightforward. Heparin requirements are increased during pregnancy, as described previously. LMWHs undergo less binding to heparin-binding proteins than unfractionated heparin, but the increased clearance and degradation are likely to decrease the effectiveness of the dose. Jacobsen et al. (47) found that pregnant women may require dalteparin dose increases of 10 -20% compared with nonpregnant women in order to reach a target anti-Xa activity. Barbour et al. (37) found that standard weight-based therapeutic doses of dalteparin, dosed every 12 hrs, were inadequate to maintain therapeutic range anticoagulation based on target anti-Xa levels. Moreover, they found that trough levels were therapeutic only 9% of the time, despite therapeutic peak levels. Therefore, although LMWHs may be safe during pregnancy, they may require monitoring of anti-Xa levels and frequent dose adjustments, similar to those of unfractionated heparin. This decreases the logistic and financial benefit of LMWHs over unfractionated heparin. Also, for the critical first 48 hrs after an acute embolic event, unfractionated heparin, with its ease of dose titration, should be used to ensure therapeutic levels. Therefore, although LMWHs remain a potential treatment option, with a possibility of logistic benefit, the endorsed benefits of LMWH over unfractionated heparin may not be supported by the data. Specifically, reduced risks of bleeding, thrombocytopenia, and osteoporotic complications have not been established for LMWHs or for LMWHs during pregnancy. These complications may be doserelated, and their incidences may increase as therapeutic dosing of LMWHs in pregnancy is accomplished with intensive monitoring and dose adjustments.
Warfarin. Coumarin derivatives cross the placenta and are associated with warfarin embryopathy. They are relatively contraindicated during pregnancy. Warfarin is thought to be safe during the first 6 wks of pregnancy, but the associated warfarin embryopathy occurs in 4 -5% of fetuses when maternal exposure occurs between 6 and 9 wks gestation. This embryopathy includes midface hypoplasia, stippled chondral calcification, scoliosis, short proximal limbs, and short phalanges (48) .
Coumarin derivatives also induce an anticoagulant effect on the fetus, and so these agents can cause fetal hemorrhage. Warfarin has been associated with central nervous system and ophthalmologic abnormalities in the fetus with exposure at any point throughout gestation, which may be secondary to intercerebral hemorrhage in the fetus (48) . If warfarin is used during pregnancy, in the event that heparin and LMWHs are contraindicated, a pregnant woman should be counseled about the risks of teratogenesis and fetal hemorrhage with the use of warfarin. The bleeding risks for both mother and fetus are greatest at delivery, and for this reason, if warfarin is used during pregnancy, heparin should be substituted for the last 2-4 wks of pregnancy.
Treatment Summary. For acute pulmonary embolism during pregnancy, the patient should receive intravenous heparin for 5 days. Given the difficulties in ensuring a constant therapeutic anticoagulation with LMWHs, these should not be used in the acute setting. Subsequently, the patient can be transitioned to subcutaneous dosing with unfractionated or LMWH for the duration of the pregnancy and 6 wks postpartum, with anti-Xa levels guiding the dosing of LMWH. Dosing should not be less frequent than every 12 hrs. If the patient has a postpartum DVT or PE, warfarin may be initiated, but the patient should be continued on intravenous heparin for 5 days or until the international normalized ratio is Ͼ2.0 for 2 days, whichever is longer.
Breastfeeding. Heparin, LMWHs, and warfarin have not been found to be secreted in breast milk in clinically significant amounts (36, 49, 50) . Postpartum women who wish to breastfeed can safely be treated with heparin, LMWH, or warfarin.
Unstable Pulmonary Embolism. Anticoagulation is the mainstay of therapy for pulmonary embolism, but in the case of massive PE, anticoagulation alone may be insufficient. Hemodynamic instability and right heart strain may lead to hypotension and death. In the case of a massive PE, supportive care and intravenous anticoagulation should be undertaken without delay. Subsequent treatment options include thrombolytics, ICV filter placement, and embolectomy.
Supportive Care and Vasopressors. If hypotension follows a massive PE, volume resuscitation should be initiated. It is important to remember, however, that normal blood pressure decreases during pregnancy and reaches its nadir at approximately 20 wks of gestation. Therefore, a normal blood pressure for a pregnant woman is lower than the normal blood pressure in a nonpregnant patient. However, although a lower blood pressure may be tolerated, hypoxia is not tolerated during pregnancy. Oxygen saturations should be maintained Ն95% if possible.
Care should also be taken in the positioning of the pregnant patient. In the supine position, the gravid uterus rests on the inferior vena cava, and in a patient who is beyond midpregnancy, this may impede venous return and decrease cardiac output. Therefore, the first maneuver for support of blood pressure is positioning in a lateral decubitus position, thus displacing the uterus off the inferior vena cava (IVC), increasing venous return and cardiac output.
If vasopressors are required, the agent should be chosen carefully. Some vasopressor agents may constrict uterine blood vessels, leading to a decrease in uterine blood flow. The effect of the vasopressor on uterine muscular tone is also important. Although the use of vasopressors is not without risk to the fetus, sustained maternal hypotension also leads to decreased uterine blood flow and fetal distress. The goal of vasopressor use is to increase systemic blood flow to perfuse vital organs. In the setting of a pulmonary embolism, perfusion of the right ventricle is particularly important, as its work demand is substantially increased, and the tissue perfusion pressure is elevated due to relative pulmonary hypertension.
The primary mechanisms of vasopressors include arterial constriction, venous constriction, and cardiac effects to increase the cardiac rate and/or contractility. These effects are often mediated through the activity of a vasopressor on the ␣-or ␤-receptor. ␣ stimulation causes vasoconstriction, mydriasis, and intestinal relaxation, whereas ␤ stimulation causes vasodilation, increase in heart rate and contractility, and bronchial and intestinal muscle relaxation (51) . The pregnant uterus has both ␣-and ␤-adrenergic receptors. ␣-receptor causes an increase in uterine muscle tone, whereas ␤-receptor stimulation causes a decrease in uterine muscle activity (51) . The vasculature of the uterus, however, has only ␣-receptors, so although ␤-stimulating agents do not affect uterine blood flow, ␣-receptor activators can cause uterine vasoconstriction with a decrease in blood flow (51) .
Thrombolytics. The experience with thrombolytic therapy in pregnant patients is minimal, and in fact, pregnancy is considered a relative contraindication for thrombolytic therapy. There are no prospective randomized trials to date that evaluate the efficacy and safety of thrombolytics during pregnancy, and these studies are unlikely to be undertaken. However, there are case reports in the literature of thrombolysis being used safely in pregnancy (52) (53) (54) , although its use is associated with a risk of bleeding complications, maternal or fetal hemorrhage, teratogenesis, and fetal loss. Because of these risks, the use of thrombolytics has been reserved for those cases in which the life of the mother is threatened. However, Ahern et al. (55) reviewed the available literature and found that thrombolytic therapy in pregnancy was associated with a very low maternal mortality rate of approximately 1%, with a 6% rate of fetal loss and a 6% rate of premature delivery. In contrast, embolectomy and cardiopulmonary bypass were associated with a 20 -40% rate of fetal loss despite low maternal mortality rate. These data must be interpreted carefully, as they are limited to case studies and care reports, and the reason for cardiopulmonary bypass was not limited to embolectomy. However, thrombolytic therapy may be a reasonable treatment for a pregnant patient with unstable pulmonary embolism. The major complication associated with thrombolytic therapy is bleeding, but the rates of hemorrhage of pregnant patients have been noted to be comparable to those of nonpregnant patients. If thrombolytic therapy is employed, recombinant tissue plasminogen activator and streptokinase are the recommended agents. Recombinant tissue plasminogen activator is a large polypeptide that does not cross the placenta. Streptokinase is also a large molecule derived from group C streptococci, which does not cross the placenta in amounts significant enough to induce fetal coagulopathy. However, streptokinase is antigenic, so patients who receive a dose should not receive a repeat dose for 6 months. Urokinase is a small molecule purified from human urine, and it does cross the placenta. It is not currently known whether urokinase induces a fetal coagulopathy, but this is a possibility. Therefore, we recommend the use of re-combinant tissue plasminogen activator or streptokinase if possible.
IVC Filters. IVC filters have been successfully used during pregnancy, and the indications for their use are the same as for the nonpregnant populations. These include a) patients with acute VTE and contraindications to anticoagulation; b) patients who have an episode of acute VTE while appropriately anticoagulated; and c) patients who are critically ill and at risk of recurrent embolism, in whom recurrent embolism is likely to be fatal (55) .
IVC filters have been associated with a small but real risk of complications, especially over the long term. Risks include migration of the filter; perforation of the aorta, duodenum, or renal pelvis; and penetration of nearby structures including vertebrae and the retroperitoneum. For these reasons, retrievable filters may be a good option in this patient population, who are likely to be young, placing them at higher risk of long-term complications from an indwelling filter. Retrievable filters must be removed within a short time period but may succeed in preventing a second embolic while initial stabilization takes place. If a pregnant patient is critically unstable from pulmonary embolism and it is believed that she is high risk of a recurrent embolic event, we recommend IVC filter placement to avoid a recurrent PE.
Embolectomy. Embolectomy is a treatment option for massive PE when conventional therapy has failed. Embolectomy is indicated to prevent death in patients who are hemodynamically unstable despite anticoagulation and vasopressors (56) . Although data are limited for the use of embolectomy in pregnancy, the early experience was associated with a high incidence of death and neurologic sequelae. Technological advances and extracorporeal bypass have significantly reduced the mortality rate associated with this procedure (55), but since it has been associated with a 20 -40% incidence of fetal loss, it must be restricted to cases in which the life of the woman is endangered. If this procedure is undertaken, pregnant patients are likely to be good surgical candidates, as they tend to be younger and healthier than the average patient with venous thromboembolic disease.
In the case of unstable pulmonary embolism in a pregnant patient, there is little conclusive evidence to guide therapy. The indications for IVC filter placement are the same as those for a nonpregnant patient. The data are lacking for both thrombolytic therapy and embolectomy, but reviews of the available case reports and case series suggest that thrombolytic therapy may be associated with a lower incidence of fetal loss than embolectomy. Therefore, it is reasonable to attempt thrombolysis with tissue plasminogen activator or streptokinase if the patient is in extremis, although there are no trials to date that establish the safety of these agents during pregnancy. Embolectomy should be reserved for cases in which the life of the mother is threatened.
CONCLUSION
The spectrum of venous thromboembolic disease continues to be a source of significant morbidity and mortality during pregnancy and the puerperium. The diagnosis requires objective testing, which can be done safely throughout pregnancy. Coumarin derivatives cross the placenta and are relatively contraindicated during pregnancy, so heparin is the mainstay of therapy. Intravenous heparin should be used in the acute setting, and then the patient can be transitioned to subcutaneous therapy with unfractionated or low-molecular weight heparin. In the case of massive PE, thrombolytics and IVC filters are considered in the nonpregnant patient and may be useful in pregnancy as well. IVC filters can be used during pregnancy, and their indications are the same as for nonpregnant patients. The data for thrombolytic therapy during pregnancy are minimal but suggest that this therapy may be useful with a low rate of maternal and fetal mortality. Embolectomy has been associated with a high rate of fetal loss and therefore should be reserved for cases in which the life of the mother is endangered.
